Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Crescent Biopharma, Inc.NASDAQ: CBIO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 financing cash flow of $6.95M (cash outflow) rose 367.4% year over year, behind the +699.2% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +326.7% a year.

Context

  • Financing cash flow amounted to 2978.5% of revenue in FY2025.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +367.4% toward the trailing-twelve-month pace of +699.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.95M-103.9% QoQ
Last fiscal yearDec 2025
$322.98M+5983301.3% YoY
LTMMar 2026
$316.04M+699.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+367.4%——
1 year+5983301.3%——
3-year CAGR+326.7%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
322.98M USD
Year-over-year change
+5983301.3%
4-year CAGR
+134.3%

Financing Cash Flow vs competitors

How CBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +699.2% is the 6th highest of 8, against a peer median of +5357.5%.
  • Financing cash flow amounts to 2659.6% of revenue for CBIO, versus a peer median of 217.4%.
CBIO Competitors
Financing Cash Flow for CBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$444.83M USD+5357.5%—167.2%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥433.38M CNY—+10.9%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$344.93M USD+4594.2%+454.4%970.5%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$327.45M USD+22878.8%-16.3%292364.3%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$316.04M USD+699.2%+326.7%2659.6%
RCUSArcus Biosciences, Inc.LTM Jun 2026$313M USD+30.4%+145.5%267.5%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$133.79M USD+14802.1%+19.6%—
MGNXMacroGenics, Inc.LTM Mar 2026$69.59M USD+16083.5%+247.3%44.3%
CGENCompugen Ltd.LTM Dec 2025$0 USD—+210.9%0.0%
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD-100.0%-46.9%—
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CBIO) —+5357.5%+82.5%217.4%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.43M)(46.69M)(36.9M)(37.88M)(149.94M)
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
Deferred Income Tax2.17K0000
Stock-Based Compensation6.09M3.86M3.56M4.77M13.3M
Change in Working Capital(1.17M)(4.66M)(2.56M)1.16M(13.37M)
Accounts Receivables0000(18M)
Inventory00000
Accounts Payables17.68K(1.14M)(102.08K)(538.81K)2.08M
Other Working Capital(1.18M)(3.52M)(2.46M)1.7M2.55M
Other Non-Cash Items749.04K828.51K864.87K814.48K78.4M
Operating Cash Flow(57.49M)(46.46M)(34.88M)(31.1M)(71.53M)
Capital Expenditures(14.94K)(84.19K)(21.39K)(9.97K)(919K)
Acquisitions (Net)00030K0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0000(72M)
Investing Cash Flow(14.94K)(84.19K)(21.39K)20.03K(72.92M)
Debt Repayment00000
Common Stock Issued10.7M4.16M28.71M5.4K5K
Common Stock Repurchased0000(177K)
Dividends Paid00000
Other Financing Activities25.03K0116.5K0323.16M
Financing Cash Flow10.72M4.16M28.82M5.4K322.98M
Effect of Forex Changes00000
Net Change in Cash(46.78M)(42.38M)(6.08M)(31.07M)178.53M
Free Cash Flow(57.5M)(46.54M)(34.9M)(31.11M)(72.45M)

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.